High on-treatment platelet reactivity (HPR): What does it mean, and does it matter?

Thrombosis and Haemostasis

Volumn 109, Issue 2, 2013, Pages 177-178

  Goto, Shinya ^a   Tomiya, Aiko ^b  

^a TOKAI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b Department of Metabolic Systems Medicine   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; DRUG METABOLITE; PRASUGREL; PURINERGIC P2Y12 RECEPTOR; TICLOPIDINE;

BLEEDING DISORDER; EDITORIAL; EVIDENCE BASED MEDICINE; HIGH ON TREATMENT PLATELET REACTIVITY; HUMAN; ISCHEMIA; PLATELET REACTIVITY; PREVALENCE; PRIORITY JOURNAL; PROTEIN BINDING; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECEPTOR BLOCKING; RECEPTOR OCCUPANCY; THROMBOSIS;

ACUTE CORONARY SYNDROME; DRUG SUBSTITUTION; FEMALE; HUMANS; MALE; PIPERAZINES; PLATELET AGGREGATION INHIBITORS; PURINERGIC P2Y RECEPTOR ANTAGONISTS; THIOPHENES; TICLOPIDINE;

EID: 84873311896     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH12-12-0910     Document Type: Editorial

References (18)

1. Saucedo J, Angiolillo DJ, Deraad R, et al.; for the SWAP Investigators. Decrease in high on-treatment platelet reactivity (HPR) prevalence on switching from clopidogrel to prasugrel: insights from the switching anti-platelet (SWAP) study. Thromb Haemost 2013; 109: 347-355.
2. CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996; 348: 1329-1339.
3. Hollopeter G, Jantzen HM, Vincent D, et al. Identification of the platelet ADP receptor targeted by antithrombotic drugs. Nature 2001; 409: 202-207.
4. Bal Dit Sollier C, Berge N, Boval B, et al. Functional variability of platelet response to clopidogrel correlates with P2Y(12) receptor occupancy. Thromb Haemost 2009; 101: 116-122.
5. Cattaneo M. Bleeding manifestations of congenital and drug-induced defects of the platelet p2y12 receptor for adenosine diphosphate. Thromb Haemost 2011; 105 (Suppl 1): S67-74.
6. Pereillo JM, Maftouh M, Andrieu A, et al. Structure and stereochemistry of the active metabolite of clopidogrel. Drug Metab Dispos 2002; 30: 1288-1295.
7. Savi P, Pereillo JM, Uzabiaga MF, et al. Identification and biological activity of the active metabolite of clopidogrel. Thromb Haemost 2000; 84: 891-896.
8. Goto S, Tamura N, Eto K, et al. Functional significance of adenosine 5'-diphosphate receptor (p2y(12) in platelet activation initiated by binding of von willebrand factor to platelet gp ibalpha induced by conditions of high shear rate. Circulation 2002; 105: 2531-2536.
9. Goto S, Ikeda Y, Murata M, et al. Epinephrine augments von willebrand factor-dependent shear-induced platelet aggregation. Circulation 1992; 86: 1859-1863.
10. Goto S, Sakai H, Goto M, et al. Enhanced shear-induced platelet aggregation in acute myocardial infarction. Circulation 1999; 99: 608-613.
11. Serebruany VL. Viewpoint: paradoxical excess mortality in the PLATO trial should be independently verified. Thromb Haemost 2011; 105: 752-759.
12. Wallentin L, Becker RC, James SK, et al. The PLATO trial reveals further opportunities to improve outcomes in patients with acute coronary syndrome. Thromb Haemost 2011; 105: 760-762.
13. Ohman EM, Roe MT. Explaining the unexpected: insights from the PLATelet inhibition and clinical Outcomes (PLATO) trial comparing ticagrelor and clopidogrel. Thromb Haemost 2011; 105: 763-765.
14. Serebruany VL, Atar D. Viewpoint: Central adjudication of myocardial infarction in outcomedriven clinical trials--common patterns in TRITON, RECORD, and PLATO? Thromb Haemost 2012; 108: 412-414.
15. Verheugt FW. Outcomes of positive randomised controlled clinical trials: double-blind or double vision? Thromb Haemost 2012; 108: 410-411.
16. Serebruany VL. Viewpoint: Reversible nature of platelet binding causing transfusion-related acute lung injury (TRALI) syndrome may explain dyspnea after ticagrelor and elinogrel. Thromb Haemost 2012; 108: 1024-1027.
17. Schrör K. 'Reversible nature of platelet binding causing transfusion-related acute lung injury (TRALI) syndrome may explain dyspnea after ticagrelor and elinogrel'-a hypothesis that remains unproven. Thromb Haemost 2012; 108: 1028-1030.
18. Gurbel PA, Roe MT, Jakubowski JA, et al. Translational platelet research in patients with coronary artery disease: what are the major knowledge gaps? Thromb Haemost 2012; 108: 12-20.